Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.-Reference-Cited by-同舟云学术

Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:8000-8000
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Spigel David R.¹,Edelman Martin J.²,O'Byrne Kenneth³,Paz-Ares Luis⁴,Shames David S.⁵,Yu Wei⁵,Paton Virginia E.⁵,Mok Tony⁶

Affiliation:

1. Sarah Cannon Research Institute, Nashville, TN

2. University of New Mexico Cancer Center, Albuquerque, NM

3. Queensland University of Technology, Brisbane, Australia

4. University Hospital Virgen del Rocío, Seville, Spain

5. Genentech, South San Francisco, CA

6. The Chinese University of Hong Kong, Hong Kong, China

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.8000

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fully automated radiolabeling of [68Ga]Ga-EMP100 targeting c-MET for PET-CT clinical imaging;EJNMMI Radiopharmacy and Chemistry;2023-10-16

2. MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome;Cancers;2022-05-14

3. Targeting un-MET needs in advanced non-small cell lung cancer;Lung Cancer;2022-02

4. HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer;Cancers;2021-06-02

5. Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis;Targeted Oncology;2020-08-31